Когда первая компания в сфере долголетия достигнет оценки в 10 млрд долларов или выше?

This is a September 4, 2021 MIT Technology Review news article about Altos Labs, a longevity-focused startup. It reports the company had raised at least $270 million, which is relevant baseline evidence for estimating whether and when a longevity company might later achieve a disclosed $10B+ post-money valuation.

This is a news article about Retro Biosciences, a longevity-focused company, highlighting its disclosed $1.8 billion valuation and a clinical milestone in Alzheimer's. It bears on the prognosis because it provides a concrete recent valuation benchmark well below the $10B resolution threshold and context on progress that could affect future valuation growth.

This is a Facebook post by STAT linking to a news report that Retro Biosciences raised funding at a disclosed $1.8 billion valuation. It is relevant because it provides a concrete, dated valuation datapoint for a longevity company, though it is well below the $10 billion resolution threshold.

This is an official Retro Biosciences blog post announcing the initial close of a new financing round. Company financing announcements are directly relevant to the question because a disclosed post-money valuation of $10B+ would resolve the prediction if Retro is the first named longevity company to reach that threshold.

This is a news report about Altos Labs launching with $3 billion in funding to pursue cellular rejuvenation. It does not disclose a $10B+ post-money valuation, but it is relevant background evidence on the scale, financing, and prominence of a leading longevity company that could plausibly reach that threshold.

This is a news/analysis page discussing Retro Biosciences' reported 2026 valuation of about $1.8 billion. It is relevant as a valuation benchmark for a named longevity company, indicating it remains well below the $10B resolution threshold.

This is a social-media news post reporting roughly $3 billion committed to Altos Labs, a longevity-focused company. It does not disclose a post-money valuation, but it is still relevant background evidence because it indicates unusually large investor backing for a named candidate in the race to a $10B+ valuation.

This appears to be a LinkedIn commentary post discussing a longevity-related startup at a disclosed $5B valuation despite lacking clinical data. It is relevant because it provides a concrete valuation datapoint below the $10B resolution threshold, which informs how close the sector may be to the forecasted milestone.